Suprazygomatic Maxillary Nerve Block in Pediatric Tonsillectomy

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

December 31, 2027

Study Completion Date

January 1, 2028

Conditions
Tonsillitis
Interventions
PROCEDURE

Suprazygomatic maxillary nerve block (SZMN) with ropivacaine

Participants will receive 15 mg/kg of Tylenol and 4 mg/kg of celecoxib (a nonsteroidal anti-inflammatory (NSAID drug) up to a maximum dose of 200 mg prior to the start of general anesthesia which will consist of gas or intravenous induction (2 mcg/kg fentanyl, 0.5 mg/kg dexamethasone). The SZMN block will be performed using 0.2 ml/kg of 0.25% ropivacaine (local anesthetic), up to a maximum dose of 5 mL. The surgery (tonsillectomy or adenotonsillectomy) will then proceed according to standard of care practices.

PROCEDURE

Suprazygomatic maxillary nerve block (SZMN) with placebo

Participants will receive 15 mg/kg of Tylenol and 4 mg/kg of celecoxib (a nonsteroidal anti-inflammatory (NSAID drug) up to a maximum dose of 200 mg prior to the start of general anesthesia. which will consist of gas or intravenous induction (2 mcg/kg fentanyl, 0.5 mg/kg dexamethasone). The SZMN block will be performed using 0.2 ml/kg of saline (placebo) up to a maximum dose of 5 mL. The surgery (tonsillectomy or adenotonsillectomy) will then proceed according to standard of care practices.

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT07176533 - Suprazygomatic Maxillary Nerve Block in Pediatric Tonsillectomy | Biotech Hunter | Biotech Hunter